Treatment with bezuclastinib plus Sutent led to safe and efficacious outcomes versus Sutent treatment alone in gastrointestinal stromal tumors.

Walker, 66, transitioned on December 26, 2025, after a two-year battle with stomach cancer (GIST). She was born in Hamilton, Bermuda on October 14, 1958, ...

Bezuclastinib's upcoming data in July 2025 could be a game-changer for COGT, offering a lucrative investment opportunity. See ...

For patients with gastrointestinal stromal tumors with liver metastases, treatment with surgery and chemotherapy has been found to have survival benefits.

A new artificial intelligence-powered tool called MISO (Multi-modal Spatial Omics) can detect cell-level characteristics of cancer by looking at data from extremely small pieces of tissue—some as ...

By staying abreast of signs and risk factors, such as persistent indigestion, unexplained weight loss, or discomfort in the ...

Chicago, IL – January 15, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks ...

Johnson & Johnson, already a big player in neuroscience drugs, is adding to its portfolio and pipeline with a deal to acquire ...

British pharmaceutical company GSK on Monday said it had agreed to buy a US company that specializes in the treatment of rare ...

GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early treatment stages.

Report top-line results during the second half of 2025 from the APEX trial. APEX is a registration-directed, global, open-label trial of bezuclastinib in patients with Advanced Systemic Mastocytosis ...